Table 5.

Analysis of Cell Cycle Distribution After Treatment with ²¹²Pb Radioimmunotherapy and Carboplatin

			Timepoint (hours)
RIT	Chemotherapy	Phase	0	6	24	48	72	96
None	None	G1	72.8±0.6
		S	16.3±0.7
		G2-M	10.9±1.3
None	Carboplatin	G1		63.6±0.9	69.9±1.1	65.8±0.6	70.8±0.1	66.5±3.0
		S		16.5±1.3	17.2±0.2	11.6±0.6	10.8±0.1	12.3±1.5
		G2-M		19.9±0.4	12.9±1.2	22.6±0.1	18.4±0.1	21.2±1.5
Trastuzumab	None	G1		ND	74.8±0.9	66.4±1.0	64.1±0.4	61.7±0.1
		S		ND	11.0±1.0	3.7±0.1	2.5±0.3	5.1±0.3
		G2-M		ND	14.2±0.1	29.9±0.8	33.5±0	33.2±0.1
Trastuzumab	Carboplatin	G1		67.5±2.5	74.9±0.4	78.2±4.1	70.7±1.4	65.9±.5
		S		20.9±0.1	5.9±1.5	2.6±0.3	3.9±0.8	4.8±0.3
		G2-M		11.6±2.6	19.2±1.2	19.2±4.4	25.4±2.3	29.3±0.1
HuIgG	None	G1		ND	68.0±0.9	67.0±1.5	71.5±1.5	65.4±0.6
		S		ND	8.1±0.4	6.7±1.2	5.7±0.2	7.7±1.1
		G2-M		ND	24.0±0.5	26.4±0.3	22.9±1.3	26.9±0.5
HuIgG	Carboplatin	G1		68.0±1.2	71.7±1.7	83.7±1.1	63.5±0.6	66.9±0.4
		S		18.8±0.2	5.3±0.1	3.2±1.2	4.5±0.4	6.1±0.1
		G2-M		13.2±1.3	23.0±1.6	13.2±0.1	32.0±0.9	27.1±0.4

The values presented are the percentage of cells in the G1-, S-, and G2-M phases of the cell cycle along with the standard deviation.

ND, not determined.